1,5-dimethylquinolin-2(1H)-one | 67200-69-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1,5-dimethylquinolin-2(1H)-one
• 英文别名: 1,2-dihydro-1,5-dimethylquinolin-2-one；1,5-Dimethylquinolin-2-one
• CAS: 67200-69-5
• 化学式: C₁₁H₁₁NO
• 分子量: 173.214
• InChiKey: ZXCHVDBNRMFCNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-Methyl-6-pent-4-enylpyridin-2-one 在 对苯醌 、 palladium dichloride 作用下， 以 1,4-二氧六环 为溶剂， 以92 %的产率得到1,5-dimethylquinolin-2(1H)-one
  参考文献：
  名称：

  一种喹啉酮类化合物的制备方法

  摘要：

  本发明公开了一种喹啉酮类化合物的制备方法，所述制备方法包括：在惰性气氛下，将式(Ⅰa′)或式(Ⅰb′)所示化合物与催化剂、氧化剂、有机溶剂接触使反应。本发明方法可高效经济、绿色地制备喹啉酮类化合物，且原料易得，操作简单，反应条件温和，具有良好的官能团耐受性和底物普适性，无需额外添加配体，具有极好的化学选择性，有望在相关的药物化学和天然产物的合成中得到应用；#imgabs0#

  公开号：

  CN117624043A

文献信息

• [EN] COT MODULATORS AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DE COT ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：GILEAD SCIENCES INC

  公开号：WO2017007689A1

  公开（公告）日：2017-01-12

  The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

  本公开涉及通常与Cot（大阪甲状腺癌）调节剂及其使用和制造方法。
• Heterocycles for use as inhibitors of leukotrienes
  申请人：Imperial Chemical Industries PLC

  公开号：US05134148A1

  公开（公告）日：1992-07-28

  The invention concerns a heterocycle of the formula I ##STR1## wherein Q is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms; A is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene; X is oxy, thio, sulphinyl, sulphonyl or imino; Ar is phenylene which may optionally bear one or two substituents or Ar is an optionally substituted 6-membered heterocyclene moiety containing up to three nitrogen atoms; R.sup.1 is hydrogen, (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl, cyano-(1-4C)alkyl or (2-4C)alkanoyl, or optionally substituted benzoyl; and R.sup.2 and R.sup.3 together form a group of the formula --A.sup.2 --X.sup.2 --A.sup.3 -- which, together with the carbon atom to which A.sup.2 and A.sup.3 are attached, defines a ring having 4 to 7 ring atoms, wherein A.sup.2 and A.sup.3, which may be the same or different, each is (1-4C)alkylene and X.sup.2 is oxy, thio, sulphinyl, sulphonyl or imino; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.

  该发明涉及式I的杂环##STR1##其中Q是一个可选择地取代的含有一个或两个氮原子的6元单环或10元双环杂环基团；A是(1-6C)烷基、(3-6C)烯基、(3-6C)炔基或环(3-6C)烷基；X是氧、硫、亚砜基、磺酰基或亚胺基；Ar是苯基，可以选择性地带有一个或两个取代基，或Ar是一个可选择地取代的含有最多三个氮原子的6元杂环基团；R.sup.1是氢、(1-6C)烷基、(3-6C)烯基、(3-6C)炔基、氰基-(1-4C)烷基或(2-4C)烷酰基，或可选择地取代的苯甲酰基；而R.sup.2和R.sup.3一起形成一个式--A.sup.2--X.sup.2--A.sup.3--的基团，与A.sup.2和A.sup.3连接的碳原子一起定义具有4到7个环原子的环，其中A.sup.2和A.sup.3，可以相同也可以不同，每个是(1-4C)烷基，而X.sup.2是氧、硫、亚砜基、磺酰基或亚胺基；或其药学上可接受的盐。该发明的化合物是5-脂氧合酶的抑制剂。
• Heterocyclic cyclic ethers
  申请人：Imperial Chemical Industries PLC

  公开号：US05196419A1

  公开（公告）日：1993-03-23

  The invention concerns a heterocyclic cyclic ether of the formula I ##STR1## wherein Q is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms; A is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene; X is oxy, thio, sulphinyl, sulphonyl or imino; Ar is phenylene which may optionally bear one or two substituents or Ar is an optionally substituted 6-membered heterocyclene moiety containing up to three nitrogen atoms; R.sup.1 and R.sup.2 together form a group of the formula --A.sup.2 --X.sup.2 --A.sup.3 -- which, together with the oxygen atom to which A.sup.2 is attached and with the carbon atom to which A.sup.3 is attached, defines a ring having 5 to 7 ring atoms, wherein A.sup.2 and A.sup.3 each is (1-3C)alkylene and X.sup.2 is oxy, thio, sulphinyl, sulphonyl or imino, and which ring may bear one, two or three substituents; and R.sup.3 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl or substituted (1-4C)alkyl; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.

  该发明涉及一种具有以下式I的杂环环氧化物 其中Q是含有一个或两个氮原子的可选择取代的6-成员单环或10-成员双环杂环基; A是(1-6C)烷基，(3-6C)烯基，(3-6C)炔基或环(3-6C)烷基; X是氧，硫，亚砜，磺酰基或亚胺; Ar是苯基，可能可选择携带一个或两个取代基，或Ar是一个可选择取代的含有最多三个氮原子的6-成员杂环基; R1和R2一起形成一个具有以下式--A2--X2--A3--的基团，与A2连接的氧原子和与A3连接的碳原子一起，定义具有5至7个环原子的环，其中A2和A3各自是(1-3C)烷基，X2是氧，硫，亚砜，磺酰基或亚胺，该环可以携带一个、两个或三个取代基; R3是氢，(1-6C)烷基，(2-6C)烯基，(2-6C)炔基或取代的(1-4C)烷基;或其药用盐。该发明的化合物是5-脂氧合酶的抑制剂。
• Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor
  申请人：ZENECA LIMITED

  公开号：US20020040002A1

  公开（公告）日：2002-04-04

  1 Compounds of formula (I), wherein: n is 1 to 6; Het is a nitrogen containing ring fused to the benzene ring on two adjacent carbon atoms to form a bicyclic ring system which ring system may be optionally substituted; R 1 is hydrogen, C 1-8 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, aryl, heteroaryl, heterocyclyl, arylC 1-6 alkyl, heteroarylC 1-6 alkyl, heterocyclylC 1-6 alkyl or C 3-8 cycloalkylC 1-6 alkyl; R 2 is C 1-6 alkyl, C 2-6 alkenyl, arylC 1-6 alkyl, heteroarylC 1-6 alkyl or the side-chain of a naturally occurring amino acid; R 3 is hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, C 4-8 cycloalkenyl, arylC 1-6 alkyl, heteroarylC 1-6 alkyl or heterocyclylC 1-6 alkyl; R 4 is hydrogen or C 1-6 alkyl; or R 3 and R 4 together with the nitrogen atom to which they are joined form a heterocyclic ring; wherein any group or ring, in R 1 -R 4 , is optionally substituted; and pharmceutically acceptable salts and in vivo hydrolysable esters thereof, are described as inhibitors of the production of Tumour Necrosis Factor and/or one or more matrix metalloproteinase enzymes. Compositions containing them and their preparation are also described.

  化合物的式子(I)，其中：n为1至6；Het是一个氮含环，在苯环上的两个相邻碳原子上融合形成一个双环系统，该环系统可以选择性地被取代；R1为氢、C1-8烷基、C2-6烯基、C2-6炔基、C3-8环烷基、芳基、杂芳基、杂环基、芳基C1-6烷基、杂芳基C1-6烷基、杂环基C1-6烷基或C3-8环烷基C1-6烷基；R2为C1-6烷基、C2-6烯基、芳基C1-6烷基、杂芳基C1-6烷基或天然氨基酸的侧链；R3为氢、C1-6烷基、C3-8环烷基、C4-8环烯基、芳基C1-6烷基、杂芳基C1-6烷基或杂环基C1-6烷基；R4为氢或C1-6烷基；或者R3和R4与它们连接的氮原子一起形成一个杂环；其中R1-R4中的任何基团或环都可以选择性地被取代；并且其药学上可接受的盐和体内可水解的酯被描述为肿瘤坏死因子和/或一个或多个基质金属蛋白酶酶的生产抑制剂。还描述了含有它们的组合物及其制备方法。
• INHIBITORS OF HCV NS5A
  申请人：PRESIDIO PHARMACEUTICALS, INC.

  公开号：US20130096101A1

  公开（公告）日：2013-04-18

  Provided herein are compounds, pharmaceutical compositions, and combination therapies for inhibition of hepatitis C.

  本文提供了抑制丙型肝炎的化合物、药物组合物和联合治疗方案。